- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Investigation of Neuroinflammatory Biomarkers and Onabotulinumtoxin A for Trigeminal Neuralgia Pain (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1624;
We designed this study to assess the safety and efficacy of BTX-A, injected according to a standardized paradigm, either as preventive monotherapy or as an add-on treatment. Through a comprehensive approach, including patient-reported outcomes and biomarker analysis, the study could potentially bring valuable insights to TN management.
- |||||||||| Tonmya (cyclobenzaprine SL) / Tonix
Effects of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) on Pain in Fibromyalgia: Results of t (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1581;
TNX-102 SL showed significant effects on the pain primary endpoint, and sleep quality, fatigue, cognitive function, patient global, FIQR-symptoms and FIQR-function. As importantly, TNX-102 SL was well tolerated without side effects relating to cognition, weight, blood pressure or sexual dysfunction.
- |||||||||| duloxetine / Generic mfg.
Navigating the Efficacy of Duloxetine in Osteoarthritis Management: A Meta-Analysis of RCT (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1578;
Duloxetine demonstrates effectiveness in addressing chronic pain and mitigating the decline in physical function associated with knee osteoarthritis (OA), while maintaining a reasonable level of tolerable adverse events. However, it does not offer a distinct advantage in alleviating joint stiffness.
- |||||||||| pregabalin / Generic mfg., duloxetine / Generic mfg.
Pregabalin & Duloxetine combination & PPAR -Gamma & Akt genes in Diabetic Peripheral Neuropathy (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1487;
The mRNA expression of PPAR-gamma was observed to be significantly ( p<0.05) more upregulated following utilization of combination pharmacotherapy of pregabalin and duloxetine as compared to pregabalin monotherapy, and it indicates longer lasting analgesic efficacy of this combination, possibly due to significant ( p<0.05) modulation of PPAR-Gamma gene, which is essentially involved in insulin metabolism pathway. There is an urgent need to undertake larger prospective, multicentric RCTs to validate our clinical findings & to substantiate our findings of mRNA expressions of PPAR-Gamma gene and Akt gene following combination pharmacotherapy in patients of DPN.
- |||||||||| ondansetron / Generic mfg., promethazine / Generic mfg.
Peripheral Mast Cells are Involved in the Fibromyalgia-Associated Painful Symptoms in Mice (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1419;
Our findings indicate that mast cells contribute to the development and maintenance of the mechanical and thermal hypersensitivity and muscle fatigue observed in the reserpine-induced experimental FM model, contributing to the substantiated construct validity of this model. It should be noted that many of the drugs used in this study are commercially available to treat other pathologies (e.g.,ketotifen, ondansetron, ketanserin, and promethazine) and would have the potential to be repositioned for FM.
- |||||||||| Remitch (nalfurafine) / Toray, Mitsubishi Tanabe, resatorvid (TAK-242) / Takeda, Akaza Bioscience
NIH HEAL Initiative Preclinical Screening Platform for Pain Program and Data Sharing (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1412;
It should be noted that many of the drugs used in this study are commercially available to treat other pathologies (e.g.,ketotifen, ondansetron, ketanserin, and promethazine) and would have the potential to be repositioned for FM. (PGI), carbamazepine (3-300 mg/kg, PO), celecoxib (3-100 mg/kg, PO), diazepam (1-30 mg/kg, PO), diclofenac sodium (1-100 mg/kg, PO), duloxetine hydrochloride (3-100 mg/kg, PO), gabapentin (10-300 mg/kg, PO), ketoprofen (0.3-10 mg/kg, PO), morphine sulfate (0.3-10 mg/kg, SC), naproxen sodium (1-100 mg/kg, PO), nalfurafine hydrochloride (1-3,000
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Botulinum toxin treatment in persistent headache after mild head trauma (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1333;
Furthermore, we found that patients fulfilling both ICD-10 and DSM-4 criteria had the highest chance to benefit from the BoNT-A injection treatment. But further placebo controlled double, blinded randomized clinical trials are needed to confirm our findings and improve patient selection criteria.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Efficacy and Safety Profile of Onabotulinum toxin-A Injection at Sphenopalatine Ganglion by Fluorosc (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1332;
But further placebo controlled double, blinded randomized clinical trials are needed to confirm our findings and improve patient selection criteria. Botulinum toxin type A injections into the sphenopalatine ganglion in patients with trigeminal neuralgia who cannot tolerate the side effects of medication and/or do not benefit from it can significantly reduce pain intensity and frequency.
- |||||||||| EFFECT OF MULTIMODAL TREATMENT ON POSTHERPETIC NEURALGIA (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1312;
We apply multimodal therapy: 1) IM administration of betamethasone 4 mg + ketorolac 30 mg + tramadol 100 mg, every 4 days for 3 times, 2) oral administration of pregabalin 75 mg twice daily + clomipramine 37.5 mg twice daily + valproic acid 250 mg twice daily + tramadol 50 mg three times a day. Multimodal pharmacological therapy, using drugs for neuropathic pain (anticonvulsants: valproic acid, pregabalin, antidepressants: clomipramine, opioids: tramadol and corticosteroids: betametazone, all of them unconventional) shows greater effectiveness in the pharmacological treatment of postherpetic neuralgia, reducing significantly the intensity of pain, reducing the complexity of pain, improving quality of life and improving sleep.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Medical Cannabinoids Therapy in Refractory Post-Herpetic Neuralgia and Recurrent Uveitis (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1274;
This patient had debilitating pain, which interfered with her daily activities and ability to work. CBD was used as a third line agent, as is currently recommended by the Canadian guidelines for neuropathic pain (5), where this patient was treated by an experienced pain specialist with training in clinical pharmacology (MO).
- |||||||||| Venous Sympathetic Block for Fibromyalgia Pain Flare-ups: a Case Report (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1266;
The intervention resulted in a significant improvement in the patient's quality of life, with substantial pain reduction and improvement in neuropathic pain assessment scores (DN4) and Visual Analog Scale (VAS). In addition, the patient was able to resume her daily life habits.
- |||||||||| clozapine / Generic mfg.
Influence of early life TRPV1-fibre activation on sensorimotor circuit development (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1168;
Following this, mice were randomly arranged in two groups to receive intraperitoneal injections (twice a day) of the DREADD ligand clozapine-N-oxide (CNO, 5 mg/kg) at one of two critical developmental periods: P8-P12 and P13-P17... These results indicate that activation of peripheral TRPV1 positive afferents can recruit two separate motor programs over development, depending upon the timing of the activation, suggesting a cross-modal maturation of sensorimotor circuits.
- |||||||||| Dynastat (parecoxib) / Pfizer
Opioid-induced hyperalgesia in a patient submit to ressection of myxoid chondrosarcoma: Case report (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1034;
The patient is a 44-year-old male, ASA II, obese, with a surgical history of cytoreductiveendoprosthesis due to myxoid chondrosarcoma in the left shoulder and subsequent follow-upfor a difficult-to-control mixed pain syndrome, using Methadone, Pregabalin, andAmitriptyline...The intraoperative anesthetic management involved a multimodal strategy,including the administration of dexamethasone, ondansetron, parecoxib, and dipyrone,followed by pre-induction with dexmedetomidine, magnesium sulfate, and lidocaine, andanesthesia induction with dextrocetamine, propofol, and rocuronium bromide. Patients on chronic opioid use, such as Methadone, may be prone to OIH, emphasizing the importance of a strategic intraoperative anesthetic management to control hyperalgesia and postoperative pain without the need for additional opioid doses, as evidenced in this case.
- |||||||||| levetiracetam / Generic mfg.
Abatement of Functional Motor Disorder in Dejerine-Roussy Syndrome upon Withdrawal of Levetiracetam (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1005;
Levetiracetam has been associated with behavioral disruption, especially in patients with fixed brain lesions; consideration should be given to withdrawal of this agent in selected settings with substitution when appropriate. Continuous video-EEG monitoring and careful attention to event semiology is helpful to discern whether events are likely to represent epileptiform activity.
- |||||||||| Tectin (tetrodotoxin) / CK Life Sci
Prophylactic Tetrodotoxin Treatment of a Rat Model of Oxaliplatin-Induced Peripheral Neuropathy (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_998;
Background & Aims: Tetrodotoxin (TTX) is a small molecule sodium channel blocker currently under investigation as a treatment for chemotherapy-induced neuropathic and cancer-related pain, with ongoing phase 2b and completed phase 3 clinical trials, respectively. In this study, we investigated the effects of prophylactic dosing with TTX or duloxetine on the development of oxaliplatin- induced neuropathic pain in rats.TTX at 8
- |||||||||| Growth Factor Concentrate in Traumatic Peripheral Neuropathy of Ulnar and Median Nerve (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_854;
GFs play important roles in peripheral nerve regeneration, including regulating cellular survival, growth, proliferation, differentiation, migration, neuroinflammation, and neurotrophic factor secretion. At the site of peripheral nerve injury, exogenous local administration of growth factor concentrate derived from platelets, creates microenvironment that supports peripheral nerve repair and regeneration.
- |||||||||| aripiprazole / Generic mfg., tramadol hydrochloride / Generic mfg.
Aripiprazole plus tramadol potentiates the anti-hyperalgesic effect and decreases opioid tolerance (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_811;
The combination of ARI plus TRA generates synergistic interactions in the antinociceptive effects and in the reduction of the development of pharmacological tolerance. A new association with potential for clinical utility in the treatment of hyperalgesia caused by NP is proposed.
- |||||||||| fentanyl citrate / Generic mfg., ketorolac / Generic mfg., nefopam / Generic mfg.
A RCT of opioid vs. non-opioid as PCA background for postoperative pain and complications in TKR (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_621;
The continuous chamber of the PCA device contained fentanyl 1200mcg for opioid group, and ketorolac tromethamine 150mg plus nefopam hydrochloride 100mg for non-opioid group (total volume 50ml, rate: 1cc/hr). In patients underwent total knee arthroplasty, PCA with opioid-based background infusion resulted in lower pain scores but higher complication rates than non-opioid infusion.
- |||||||||| olanzapine / Generic mfg., carbamazepine / Generic mfg., quetiapine / Generic mfg.
Journal: XOB: A novel phenylalkylamine antagonist of 5-HT2A receptors and voltage-gated sodium channels. (Pubmed Central) - Jul 17, 2024
Significance Statement We synthesized a novel small molecule (XOB) that simultaneously antagonizes two key therapeutic targets of bipolar disorder, 5-HT2A receptors and voltage-gated sodium channels (VGSCs), in heterologous cells, and inhibits the intrinsic excitability of mouse prefrontal cortex layer V pyramidal neurons in brain slices. XOB represents a valuable new proof-of-principle tool for future preclinical investigations and provides a novel molecular approach to the pharmacological treatment of complex neuropsychiatric disease, which often requires a combination of therapeutics for sufficient patient benefit.
- |||||||||| amitriptyline / Generic mfg.
Journal: Exposure Effects of Environmentally Relevant Concentrations of the Tricyclic Antidepressant Amitriptyline in Early Life Stage Zebrafish. (Pubmed Central) - Jul 17, 2024
The lack of any response on the features of physiology and behavior we measured at concentrations found in the environment would indicate that AMI poses a relatively low level of risk to fish populations. The pseudopersistence and likely presence of multiple drugs acting via the same mechanism of action, however, together with a global trend for increased prescription rates, mean that this risk may be underestimated using current ecotoxicological assessment paradigms.
- |||||||||| lithium carbonate ER / Generic mfg.
Journal, Adherence: Treatment of bipolar depression: clinical practice vs. adherence to guidelines-data from a Bavarian drug surveillance project. (Pubmed Central) - Jul 17, 2024
Of the patients, 38% were not administered any drug explicitly recommended for treatment of BPD, that is, quetiapine, lamotrigine, carbamazepine, or olanzapine...Prescription rates of venlafaxine (21% to 14%) and tricyclic antidepressants (9% to 6%) decreased significantly from the first (2014-2016) to the last (2020-2022) observed time period...Only two patients were administered a combination of olanzapine and fluoxetine...Increase in lithium prescription is an encouraging development due to its unique efficacy in maintenance treatment. To improve the quality of clinical practice guideline implementation, more randomized controlled trials should
- |||||||||| cyclobenzaprine / Generic mfg., ibuprofen / Generic mfg., duloxetine / Generic mfg.
Journal: Levator Labii Superioris Alaeque Nasi Targeted Botulinum Toxin Injection for Treatment of Perinasal Facial Discomfort and Snarling. (Pubmed Central) - Jul 16, 2024
After the first injection, the patient reported his pain had significantly improved and was relieved to be off of chronic pain medications. Our case demonstrates, what increasing literature further also supports: botulinum toxin is becoming a potential effective treatment for a breadth of spasticity disorders with a more targeted mechanism, and more manageable treatment plan, while simultaneously improving the patient's quality of life.
- |||||||||| bexicaserin (LP352) / Longboard Pharma
Review, Journal: Evaluating bexicaserin for the treatment of Developmental Epileptic Encephalopathies. (Pubmed Central) - Jul 16, 2024
Monitoring pharmacological interactions and addressing central nervous system comorbidities are crucial for optimizing treatment strategies. Further research is needed to elucidate bexicaserin's mechanisms and potential antiepileptogenic effects.
- |||||||||| olanzapine / Generic mfg.
PK/PD data, Journal: Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders. (Pubmed Central) - Jul 16, 2024
The results from a simulation suggested the oral olanzapine doses required for male and female pediatric patients weighing between 40-60?kg without co-medication were 10-15?mg/day and 7.5-10?mg/day, respectively, and dosage adjustments should be based on sex and body weight; and co-administrated with valproate, sertraline, or fluvoxamine. This model may help individualize optimum dosing of oral olanzapine for pediatric patients.
- |||||||||| Trial completion, Trial completion date: Electronic Training of Elderly Depression With Cognitive Impairment (clinicaltrials.gov) - Jul 16, 2024
P=N/A, N=128, Completed,
This model may help individualize optimum dosing of oral olanzapine for pediatric patients. Recruiting --> Completed | Trial completion date: Jan 2024 --> Aug 2023
- |||||||||| imipramine / Generic mfg., fluoxetine / Generic mfg., haloperidol / Generic mfg.
Preclinical, Journal: The sinking platform test: a novel paradigm to measure persistence in animal models. (Pubmed Central) - Jul 15, 2024
Finally, comparing transcriptomic profiles of the prefrontal cortex of mice with high and low SPT performance revealed significant enrichment of immediate-early genes known to shape susceptibility for chronic stress. These findings highlight the potential of SPT as a promising method to uncover the biological mechanisms of persistence and evaluate novel interventions to enhance this response.
- |||||||||| lacosamide / Generic mfg., mirtazapine / Generic mfg.
Biomarker, Clinical, Observational data, Preclinical, Retrospective data, Review, Journal: A case of lacosamide and mirtazapine self-poisoning. (Pubmed Central) - Jul 15, 2024
The synergistically central nervous system depressive and cardiotoxic effects of these drugs may have contributed to the cause of death. We concluded that the cause of death in this case was lacosamide and mirtazapine poisoning.
- |||||||||| Daxxify (daxibotulinumtoxinA-lanm) / Revance Therap
Journal: DaxibotulinumtoxinA (Daxxify) for frown lines. (Pubmed Central) - Jul 15, 2024
Future studies using higher doses and repeated administration should investigate if agomelatine behavioral and physiological effects could be detected in human experimental anxiety models. No abstract available
|
